| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.776 | 0.002 | 0.776 | Phosphodiesterase 3B inhibitor | 0.429 0.003 DBMET00772 0.1 0.011 DBMET00676 | ||
| 0.697 | 0.002 | 0.697 | Phosphodiesterase III inhibitor | 0.392 0.004 DBMET00772 0.089 0.029 DBMET00676 | ||
| 0.657 | 0.004 | 0.657 | Cyclic AMP phosphodiesterase inhibitor | 0.449 0.01 DBMET00772 0.179 0.112 DBMET00676 | ||
| 0.511 | 0.022 | 0.511 | Immunomodulator | 0.403 0.043 DBMET00772 0.308 0.078 DBMET00676 | ||
| 0.449 | 0.004 | 0.449 | Phosphodiesterase 3A inhibitor | 0.207 0.007 DBMET00772 0.08 0.056 DBMET00676 | ||
| 0.471 | 0.035 | 0.551 | Vasodilator, peripheral | 0.551 0.021 DBMET00772 | DBMET00772 | |
| 0.464 | 0.037 | 0.543 | GABA C receptor rho-3 antagonist | 0.423 0.052 DBMET00772 0.543 0.016 DBMET00676 | DBMET00676 | |
| 0.445 | 0.039 | 0.445 | Antithrombotic | 0.316 0.078 DBMET00772 | ||
| 0.424 | 0.023 | 0.424 | Platelet antagonist | 0.227 0.083 DBMET00772 | ||
| 0.381 | 0.001 | 0.381 | Alpha 1L adrenoreceptor antagonist | 0.299 0.002 DBMET00772 | ||
| 0.372 | 0.009 | 0.372 | Phosphodiesterase inhibitor | |||
| 0.374 | 0.014 | 0.374 | Interleukin-1 receptor-associated protein kinase 1 inhibitor | 0.318 0.026 DBMET00772 0.304 0.03 DBMET00676 | ||
| 0.304 | 0.005 | 0.304 | Polo-like kinase-4 inhibitor | 0.138 0.044 DBMET00772 0.126 0.052 DBMET00676 | ||
| 0.347 | 0.055 | 0.347 | Nootropic | 0.339 0.058 DBMET00676 | ||
| 0.326 | 0.04 | 0.35 | Vasodilator | 0.35 0.033 DBMET00772 | DBMET00772 | |
| 0.358 | 0.109 | 0.361 | 5 Hydroxytryptamine release inhibitor | 0.33 0.134 DBMET00772 0.361 0.106 DBMET00676 | DBMET00676 | |
| 0.361 | 0.138 | 0.406 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.332 0.172 DBMET00772 0.406 0.096 DBMET00676 | DBMET00676 | |
| 0.201 | 0.005 | 0.201 | Interleukin 12 antagonist | 0.156 0.011 DBMET00772 0.169 0.008 DBMET00676 | ||
| 0.264 | 0.069 | 0.264 | Interleukin agonist | 0.238 0.088 DBMET00772 0.247 0.081 DBMET00676 | ||
| 0.22 | 0.027 | 0.22 | Glycogen synthase kinase-3 inhibitor | |||
| 0.2 | 0.028 | 0.2 | Glycogen synthase kinase-3 beta inhibitor | |||
| 0.306 | 0.137 | 0.306 | Analgesic | 0.244 0.188 DBMET00772 | ||
| 0.153 | 0.01 | 0.153 | Phosphodiesterase XI inhibitor | |||
| 0.153 | 0.01 | 0.153 | Phosphodiesterase 11A inhibitor | |||
| 0.16 | 0.021 | 0.16 | DNA directed RNA polymerase inhibitor | 0.115 0.041 DBMET00772 0.132 0.031 DBMET00676 | ||
| 0.163 | 0.033 | 0.163 | Ferrochelatase inhibitor | 0.135 0.045 DBMET00772 0.136 0.044 DBMET00676 | ||
| 0.149 | 0.019 | 0.149 | Interleukin 2 antagonist | 0.118 0.049 DBMET00772 0.128 0.034 DBMET00676 | ||
| 0.139 | 0.013 | 0.19 | Glutamate release inhibitor | 0.086 0.072 DBMET00772 0.19 0.005 DBMET00676 | DBMET00676 | |
| 0.132 | 0.013 | 0.132 | Purinergic P2 antagonist | 0.1 0.021 DBMET00772 | ||
| 0.161 | 0.06 | 0.19 | GABA C receptor rho-2 antagonist | 0.167 0.054 DBMET00772 0.19 0.035 DBMET00676 | DBMET00676 | |
| 0.188 | 0.092 | 0.252 | Anticonvulsant | 0.252 0.057 DBMET00772 | DBMET00772 | |
| 0.122 | 0.026 | 0.122 | mTOR complex 1 inhibitor | |||
| 0.192 | 0.103 | 0.308 | Nitric-oxide synthase stimulant | 0.185 0.118 DBMET00772 0.308 0.01 DBMET00676 | DBMET00676 | |
| 0.23 | 0.143 | 0.251 | Interleukin 2 agonist | 0.251 0.117 DBMET00772 | DBMET00772 | |
| 0.102 | 0.016 | 0.178 | 5 Hydroxytryptamine 3A antagonist | 0.178 0.004 DBMET00676 | DBMET00676 | |
| 0.119 | 0.037 | 0.192 | Electrolyte absorption antagonist | 0.192 0.009 DBMET00772 0.177 0.012 DBMET00676 | DBMET00772 | |
| 0.1 | 0.018 | 0.244 | 5 Hydroxytryptamine 3 antagonist | 0.055 0.042 DBMET00772 0.244 0.005 DBMET00676 | DBMET00676 | |
| 0.116 | 0.038 | 0.116 | Alpha 1 adrenoreceptor antagonist | |||
| 0.097 | 0.026 | 0.097 | Transforming growth factor beta 3 antagonist | 0.084 0.052 DBMET00772 | ||
| 0.101 | 0.03 | 0.101 | HIV-1 reverse transcriptase inhibitor | 0.092 0.035 DBMET00772 0.072 0.048 DBMET00676 | ||
| 0.122 | 0.052 | 0.174 | EphA2 antagonist | 0.174 0.021 DBMET00676 | DBMET00676 | |
| 0.095 | 0.026 | 0.095 | CDC7 inhibitor | 0.067 0.047 DBMET00676 | ||
| 0.078 | 0.016 | 0.078 | Ca(v)3.2 blocker | |||
| 0.257 | 0.197 | 0.257 | Calcium channel L-type activator | |||
| 0.115 | 0.057 | 0.181 | Nav1.4 sodium channel blocker | 0.095 0.084 DBMET00772 0.181 0.024 DBMET00676 | DBMET00676 | |
| 0.068 | 0.013 | 0.071 | Histamine H4 receptor antagonist | 0.071 0.012 DBMET00676 | DBMET00676 | |
| 0.075 | 0.022 | 0.075 | Corticotropin releasing factor 2 receptor antagonist | |||
| 0.103 | 0.055 | 0.103 | Alpha adrenoreceptor antagonist | |||
| 0.067 | 0.019 | 0.067 | Purinergic P2X antagonist | 0.05 0.033 DBMET00772 | ||
| 0.076 | 0.03 | 0.076 | 5 Hydroxytryptamine 3 agonist | 0.058 0.052 DBMET00676 | ||
| 0.087 | 0.041 | 0.087 | Alpha 1a adrenoreceptor antagonist | |||
| 0.109 | 0.066 | 0.163 | 5 Hydroxytryptamine 3A agonist | 0.163 0.029 DBMET00676 | DBMET00676 | |
| 0.066 | 0.026 | 0.066 | Phosphodiesterase II inhibitor | |||
| 0.158 | 0.118 | 0.247 | Ca2+/calmodulin-dependent kinase II beta inhibitor | 0.247 0.052 DBMET00772 0.221 0.063 DBMET00676 | DBMET00772 | |
| 0.222 | 0.182 | 0.227 | Calcium channel activator | 0.227 0.176 DBMET00676 | DBMET00676 | |
| 0.05 | 0.014 | 0.066 | Phenylethanolamine N methyltransferase inhibitor | 0.047 0.017 DBMET00772 0.066 0.005 DBMET00676 | DBMET00676 | |
| 0.12 | 0.084 | 0.12 | Sodium channel blocker | |||
| 0.105 | 0.07 | 0.14 | GABA C receptor antagonist | 0.098 0.082 DBMET00772 0.14 0.036 DBMET00676 | DBMET00676 | |
| 0.075 | 0.043 | 0.075 | CDK2/cyclin E2 inhibitor | 0.065 0.055 DBMET00676 | ||
| 0.058 | 0.025 | 0.058 | Phosphodiesterase 2A inhibitor | |||
| 0.076 | 0.046 | 0.076 | Phosphodiesterase V inhibitor | |||
| 0.05 | 0.021 | 0.05 | Dipeptidyl peptidase IV inhibitor | |||
| 0.124 | 0.097 | 0.128 | CC chemokine 6 receptor antagonist | 0.122 0.107 DBMET00772 0.128 0.08 DBMET00676 | DBMET00676 | |
| 0.115 | 0.09 | 0.115 | Sodium channel (voltage-gated) blocker | |||
| 0.028 | 0.004 | 0.029 | Granulocyte colony stimulating factor receptor agonist | 0.026 0.004 DBMET00772 0.029 0.004 DBMET00676 | DBMET00676 | |
| 0.048 | 0.026 | 0.048 | Phosphodiesterase 6C inhibitor | |||
| 0.061 | 0.039 | 0.103 | Potassium channel (Ca-activated) blocker | 0.103 0.009 DBMET00676 | DBMET00676 | |
| 0.054 | 0.034 | 0.054 | Dipeptidyl peptidase inhibitor | |||
| 0.062 | 0.042 | 0.081 | NMDA 2C receptor antagonist | 0.059 0.046 DBMET00772 0.081 0.025 DBMET00676 | DBMET00676 | |
| 0.04 | 0.02 | 0.043 | Integrin alpha1beta1 antagonist | 0.039 0.025 DBMET00772 0.043 0.015 DBMET00676 | DBMET00676 | |
| 0.049 | 0.029 | 0.049 | CC chemokine 4 receptor antagonist | |||
| 0.056 | 0.039 | 0.056 | Phosphodiesterase 4C inhibitor | |||
| 0.069 | 0.054 | 0.069 | Alpha 1b adrenoreceptor antagonist | |||
| 0.08 | 0.065 | 0.109 | Antineoplastic alkaloid | 0.109 0.042 DBMET00772 | DBMET00772 | |
| 0.067 | 0.053 | 0.067 | Phosphodiesterase 5A inhibitor | |||
| 0.069 | 0.054 | 0.069 | Polo-like kinase-2 inhibitor | |||
| 0.08 | 0.066 | 0.116 | NMDA receptor antagonist | 0.116 0.037 DBMET00772 0.114 0.038 DBMET00676 | DBMET00772 | |
| 0.104 | 0.092 | 0.104 | Sphingosine 1-phosphate receptor 2 agonist | |||
| 0.082 | 0.071 | 0.103 | NADH dehydrogenase inhibitor | 0.103 0.041 DBMET00772 0.101 0.043 DBMET00676 | DBMET00772 | |
| 0.068 | 0.057 | 0.07 | Phospholipase D inhibitor | 0.07 0.052 DBMET00676 | DBMET00676 | |
| 0.09 | 0.08 | 0.169 | Nav1.1 sodium channel blocker | 0.169 0.026 DBMET00772 0.132 0.041 DBMET00676 | DBMET00772 | |
| 0.034 | 0.026 | 0.034 | Purinergic P2X7 antagonist | |||
| 0.074 | 0.066 | 0.074 | Glycine receptor antagonist | 0.072 0.07 DBMET00772 | ||
| 0.073 | 0.065 | 0.073 | Chymotrypsin inhibitor | |||
| 0.03 | 0.023 | 0.042 | Potassium channel small-conductance Ca-activated activator | 0.042 0.014 DBMET00676 | DBMET00676 | |
| 0.023 | 0.019 | 0.023 | NMDA receptor glycine site antagonist | |||
| 0.071 | 0.068 | 0.071 | Histamine H1 receptor antagonist | |||
| 0.077 | 0.076 | 0.098 | mTOR complex 2 inhibitor | 0.098 0.035 DBMET00676 | DBMET00676 | |
| 0.04 | 0.039 | 0.051 | Potassium channel small-conductance Ca-activated blocker | 0.051 0.024 DBMET00676 | DBMET00676 | |
| 0.03 | 0.032 | 0.042 | Protein kinase (CK2) beta inhibitor | 0.042 0.011 DBMET00676 | DBMET00676 | |
| 0.094 | 0.096 | 0.104 | Nav1.5 sodium channel blocker | 0.104 0.079 DBMET00676 | DBMET00676 | |
| 0.161 | 0.163 | 0.174 | Cardiotonic | 0.174 0.147 DBMET00772 | DBMET00772 | |
| 0.162 | 0.165 | 0.206 | 5 Hydroxytryptamine 3E antagonist | 0.206 0.053 DBMET00676 | DBMET00676 | |
| 0.13 | 0.136 | 0.219 | Interleukin antagonist | 0.219 0.074 DBMET00676 | DBMET00676 | |
| 0.022 | 0.029 | 0.026 | Complement factor 1r inhibitor | 0.026 0.017 DBMET00676 | DBMET00676 | |
| 0.06 | 0.067 | 0.072 | Benzodiazepine agonist | 0.072 0.048 DBMET00772 | DBMET00772 | |
| 0.084 | 0.091 | 0.128 | GABA C receptor rho-1 antagonist | 0.09 0.078 DBMET00772 0.128 0.033 DBMET00676 | DBMET00676 | |
| 0.038 | 0.047 | 0.044 | Alpha 1L adrenoreceptor agonist | 0.044 0.027 DBMET00676 | DBMET00676 | |
| 0.06 | 0.073 | 0.069 | Alpha 2a adrenoreceptor antagonist | 0.069 0.058 DBMET00676 | DBMET00676 | |
| 0.012 | 0.025 | 0.026 | Prokineticin receptor 1 antagonist | 0.026 0.004 DBMET00676 | DBMET00676 | |
| 0.033 | 0.047 | 0.046 | NMDA receptor subunit 3B antagonist | 0.046 0.028 DBMET00676 | DBMET00676 | |
| 0.004 | 0.018 | 0.009 | DNA topoisomerase III inhibitor | 0.009 0.004 DBMET00676 | DBMET00676 | |
| 0.054 | 0.068 | 0.06 | Aryl hydrocarbon receptor antagonist | 0.06 0.054 DBMET00676 | DBMET00676 | |
| 0.031 | 0.046 | 0.068 | CDK5/p25 inhibitor | 0.068 0.012 DBMET00676 | DBMET00676 | |
| 0.021 | 0.037 | 0.033 | Thymidine phosphorylase inhibitor | 0.024 0.023 DBMET00772 0.033 0.009 DBMET00676 | DBMET00676 | |
| 0.047 | 0.064 | 0.108 | Alpha 2 adrenoreceptor agonist | 0.108 0.013 DBMET00676 | DBMET00676 | |
| 0.079 | 0.098 | 0.136 | Cyclin-dependent kinase 5 inhibitor | 0.136 0.048 DBMET00676 | DBMET00676 | |
| 0.045 | 0.065 | 0.052 | Epithelial sodium channel blocker | 0.052 0.045 DBMET00676 | DBMET00676 | |
| 0.066 | 0.086 | 0.128 | Histamine N-methyltransferase inhibitor | 0.128 0.024 DBMET00676 | DBMET00676 | |
| 0.105 | 0.126 | 0.126 | Diuretic | 0.126 0.098 DBMET00676 | DBMET00676 | |
| 0.031 | 0.052 | 0.046 | 5 Hydroxytryptamine 2B agonist | 0.046 0.016 DBMET00676 | DBMET00676 | |
| 0.112 | 0.133 | 0.122 | Cyclin-dependent kinase 8 inhibitor | 0.122 0.115 DBMET00676 | DBMET00676 | |
| 0.097 | 0.118 | 0.285 | Nav1.2 sodium channel blocker | 0.285 0.017 DBMET00676 | DBMET00676 | |
| 0.178 | 0.201 | 0.232 | 5 Hydroxytryptamine uptake stimulant | 0.232 0.1 DBMET00676 | DBMET00676 | |
| 0.049 | 0.073 | 0.204 | 5 Hydroxytryptamine 5A antagonist | 0.204 0.005 DBMET00676 | DBMET00676 | |
| 0.157 | 0.182 | 0.318 | RNA-directed DNA polymerase inhibitor | 0.189 0.117 DBMET00772 0.318 0.028 DBMET00676 | DBMET00676 | |
| 0.042 | 0.07 | 0.06 | NMDA receptor glycine site agonist | 0.06 0.046 DBMET00676 | DBMET00676 | |
| 0.01 | 0.038 | 0.022 | Histamine H4 receptor agonist | 0.022 0.01 DBMET00676 | DBMET00676 | |
| 0.075 | 0.104 | 0.149 | GABA C receptor agonist | 0.149 0.034 DBMET00676 | DBMET00676 | |
| 0.044 | 0.078 | 0.198 | 5 Hydroxytryptamine 5 antagonist | 0.198 0.005 DBMET00676 | DBMET00676 | |
| 0.021 | 0.06 | 0.034 | NMDA receptor subunit 3A antagonist | 0.034 0.03 DBMET00676 | DBMET00676 | |
| 0.046 | 0.085 | 0.084 | Alpha adrenoreceptor agonist | 0.084 0.035 DBMET00676 | DBMET00676 | |
| 0.035 | 0.078 | 0.047 | Potassium channel (ATP-sensitive) activator | 0.047 0.036 DBMET00676 | DBMET00676 | |
| 0.036 | 0.08 | 0.049 | Potassium channel (Inward rectifier) activator | 0.049 0.038 DBMET00676 | DBMET00676 | |
| 0.069 | 0.113 | 0.093 | UDP-glucose 4-epimerase inhibitor | 0.093 0.07 DBMET00772 | DBMET00772 | |
| 0.069 | 0.114 | 0.168 | 5 Hydroxytryptamine antagonist | 0.168 0.043 DBMET00676 | DBMET00676 | |
| 0.065 | 0.113 | 0.109 | Pim-3 kinase inhibitor | 0.109 0.038 DBMET00676 | DBMET00676 | |
| 0.056 | 0.11 | 0.082 | Potassium channel (Ca-activated) activator | 0.082 0.073 DBMET00676 | DBMET00676 | |
| 0.163 | 0.217 | 0.232 | Tyrosine 3 hydroxylase inhibitor | 0.232 0.087 DBMET00676 | DBMET00676 | |
| 0.067 | 0.123 | 0.098 | D-Ala-D-Ala ligase inhibitor | 0.098 0.031 DBMET00676 | DBMET00676 | |
| 0.035 | 0.093 | 0.065 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.065 0.029 DBMET00676 | DBMET00676 | |
| 0.075 | 0.134 | 0.16 | Nav1.3 sodium channel blocker | 0.16 0.041 DBMET00676 | DBMET00676 | |
| 0.068 | 0.129 | 0.101 | Aurora-B kinase inhibitor | 0.101 0.081 DBMET00676 | DBMET00676 | |
| 0.069 | 0.132 | 0.109 | GABA receptor agonist | 0.107 0.07 DBMET00772 0.109 0.067 DBMET00676 | DBMET00676 | |
| 0.101 | 0.164 | 0.157 | Polo-like kinase-3 inhibitor | 0.157 0.076 DBMET00676 | DBMET00676 | |
| 0.032 | 0.096 | 0.05 | Protein kinase C eta inhibitor | 0.05 0.043 DBMET00772 | DBMET00772 | |
| 0.06 | 0.124 | 0.109 | Potassium channel activator | 0.109 0.04 DBMET00772 0.095 0.053 DBMET00676 | DBMET00772 | |
| 0.008 | 0.072 | 0.025 | Hypoxanthine phosphoribosyltransferase inhibitor | 0.025 0.022 DBMET00676 | DBMET00676 | |
| 0.005 | 0.07 | 0.011 | Purine nucleoside phosphorylase inhibitor | 0.011 0.009 DBMET00676 | DBMET00676 | |
| 0.006 | 0.072 | 0.019 | Cyclin T1 inhibitor | 0.019 0.011 DBMET00676 | DBMET00676 | |
| 0.035 | 0.101 | 0.094 | NMDA 2 receptor antagonist | 0.094 0.035 DBMET00676 | DBMET00676 | |
| 0.007 | 0.078 | 0.022 | Alpha 2a adrenoreceptor agonist | 0.022 0.008 DBMET00676 | DBMET00676 | |
| 0.023 | 0.095 | 0.037 | Tryptophan 5 hydroxylase inhibitor | 0.037 0.022 DBMET00676 | DBMET00676 | |
| 0.024 | 0.101 | 0.083 | Dihydrofolate reductase inhibitor | 0.083 0.005 DBMET00676 | DBMET00676 | |
| 0.068 | 0.148 | 0.135 | Protein kinase C gamma inhibitor | 0.134 0.042 DBMET00772 0.135 0.041 DBMET00676 | DBMET00676 | |
| 0.026 | 0.109 | 0.044 | Histamine H1 receptor agonist | 0.044 0.029 DBMET00676 | DBMET00676 | |
| 0.027 | 0.109 | 0.043 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.043 0.026 DBMET00676 | DBMET00676 | |
| 0.04 | 0.128 | 0.078 | Nicotinic alpha4beta2 receptor antagonist | 0.078 0.052 DBMET00676 | DBMET00676 | |
| 0.045 | 0.135 | 0.118 | Alpha 2 adrenoreceptor antagonist | 0.118 0.037 DBMET00676 | DBMET00676 | |
| 0.009 | 0.099 | 0.024 | Alpha 2b adrenoreceptor agonist | 0.024 0.006 DBMET00676 | DBMET00676 | |
| 0.08 | 0.171 | 0.329 | Peroxidase inhibitor | 0.329 0.032 DBMET00676 | DBMET00676 | |
| 0.117 | 0.208 | 0.133 | Ca2+-transporting ATPase inhibitor | 0.133 0.102 DBMET00676 | DBMET00676 | |
| 0.045 | 0.137 | 0.06 | Kallikrein 7 inhibitor | 0.06 0.056 DBMET00772 | DBMET00772 | |
| 0.008 | 0.103 | 0.021 | Imidazoline I1 receptor antagonist | 0.021 0.014 DBMET00676 | DBMET00676 | |
| 0.077 | 0.173 | 0.158 | Interleukin 8 antagonist | 0.12 0.062 DBMET00772 0.158 0.029 DBMET00676 | DBMET00676 | |
| 0.028 | 0.124 | 0.07 | 5 Hydroxytryptamine 2A agonist | 0.07 0.037 DBMET00676 | DBMET00676 | |
| 0.053 | 0.152 | 0.095 | Ephrin antagonist | 0.095 0.067 DBMET00676 | DBMET00676 | |
| 0.021 | 0.121 | 0.072 | Plasminogen activator inhibitor | 0.072 0.031 DBMET00772 | DBMET00772 | |
| 0.127 | 0.232 | 0.33 | 5 Hydroxytryptamine release stimulant | 0.33 0.061 DBMET00676 | DBMET00676 | |
| 0.087 | 0.194 | 0.227 | Dual specificity tyrosine-phosphorylation regulated kinase 3 inhibitor | 0.227 0.058 DBMET00676 | DBMET00676 | |
| 0.144 | 0.252 | 0.335 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | 0.335 0.043 DBMET00772 | DBMET00772 | |
| 0.025 | 0.135 | 0.048 | Histamine agonist | 0.048 0.044 DBMET00676 | DBMET00676 | |
| 0.099 | 0.211 | 0.174 | MAP kinase 3 inhibitor | 0.126 0.117 DBMET00772 0.174 0.04 DBMET00676 | DBMET00676 | |
| 0.005 | 0.117 | 0.02 | Sodium/hydrogen exchanger inhibitor | 0.02 0.009 DBMET00676 | DBMET00676 | |
| 0.058 | 0.171 | 0.104 | Protein kinase C zeta inhibitor | 0.096 0.056 DBMET00772 0.104 0.045 DBMET00676 | DBMET00676 | |
| 0.049 | 0.163 | 0.242 | HIV-1 integrase (Overall Integration) inhibitor | 0.242 0.005 DBMET00676 | DBMET00676 | |
| 0.042 | 0.157 | 0.103 | Myeloperoxidase inhibitor | 0.103 0.031 DBMET00676 | DBMET00676 | |
| 0.041 | 0.158 | 0.129 | Protein kinase (CK2) inhibitor | 0.129 0.043 DBMET00676 | DBMET00676 | |
| 0.03 | 0.148 | 0.117 | Phenylalanine 4-hydroxylase inhibitor | 0.117 0.019 DBMET00676 | DBMET00676 | |
| 0.055 | 0.173 | 0.092 | MAP kinase kinase 7 inhibitor | 0.092 0.022 DBMET00676 | DBMET00676 | |
| 0.018 | 0.137 | 0.059 | Thymidylate synthase inhibitor | 0.059 0.018 DBMET00676 | DBMET00676 | |
| 0.056 | 0.181 | 0.086 | Granulocyte macrophage colony stimulating factor agonist | 0.086 0.059 DBMET00676 | DBMET00676 | |
| 0.041 | 0.165 | 0.077 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.077 0.042 DBMET00676 | DBMET00676 | |
| 0.067 | 0.195 | 0.405 | Ca2+/calmodulin-dependent kinase II gamma inhibitor | 0.198 0.065 DBMET00772 0.405 0.017 DBMET00676 | DBMET00676 | |
| 0.05 | 0.179 | 0.125 | GABA B receptor agonist | 0.125 0.006 DBMET00676 | DBMET00676 | |
| 0.007 | 0.138 | 0.027 | CXC chemokine 2 receptor antagonist | 0.027 0.017 DBMET00676 | DBMET00676 | |
| 0.017 | 0.154 | 0.046 | Histamine H2 receptor agonist | 0.046 0.026 DBMET00676 | DBMET00676 | |
| 0.053 | 0.195 | 0.099 | Lanosterol 14 alpha demethylase inhibitor | 0.099 0.057 DBMET00676 | DBMET00676 | |
| 0.054 | 0.197 | 0.099 | Beta glucuronidase inhibitor | 0.099 0.072 DBMET00772 | DBMET00772 | |
| 0.013 | 0.156 | 0.045 | NMDA 2A receptor antagonist | 0.045 0.043 DBMET00676 | DBMET00676 | |
| 0.062 | 0.205 | 0.131 | Ca2+/calmodulin-dependent kinase II delta inhibitor | 0.131 0.076 DBMET00676 | DBMET00676 | |
| 0.005 | 0.149 | 0.028 | Alpha 2c adrenoreceptor agonist | 0.028 0.005 DBMET00676 | DBMET00676 | |
| 0.081 | 0.231 | 0.108 | DNA repair enzyme inhibitor | 0.108 0.101 DBMET00676 | DBMET00676 | |
| 0.023 | 0.175 | 0.072 | NMDA 2B receptor antagonist | 0.072 0.024 DBMET00676 | DBMET00676 | |
| 0.06 | 0.213 | 0.127 | Src kinase inhibitor | 0.127 0.102 DBMET00676 | DBMET00676 | |
| 0.038 | 0.192 | 0.162 | Protein kinase (CK2) alpha inhibitor | 0.162 0.035 DBMET00676 | DBMET00676 | |
| 0.009 | 0.163 | 0.052 | Diamine oxidase inhibitor | 0.052 0.013 DBMET00676 | DBMET00676 | |
| 0.019 | 0.174 | 0.059 | 5 Hydroxytryptamine 7 antagonist | 0.059 0.046 DBMET00676 | DBMET00676 | |
| 0.065 | 0.22 | 0.197 | CDC-like kinase 4 inhibitor | 0.197 0.069 DBMET00676 | DBMET00676 | |
| 0.005 | 0.161 | 0.021 | Vitronectin receptor antagonist | 0.021 0.014 DBMET00676 | DBMET00676 | |
| 0.089 | 0.245 | 0.253 | Ca2+/calmodulin-dependent protein kinase inhibitor | 0.253 0.056 DBMET00676 | DBMET00676 | |
| 0.011 | 0.167 | 0.041 | Dihydropteroate synthase inhibitor | 0.041 0.026 DBMET00676 | DBMET00676 | |
| 0.046 | 0.203 | 0.093 | Insulin receptor antagonist | 0.093 0.071 DBMET00676 | DBMET00676 | |
| 0.052 | 0.211 | 0.152 | Nav1.6 sodium channel blocker | 0.152 0.051 DBMET00676 | DBMET00676 | |
| 0.05 | 0.209 | 0.14 | Phosphodiesterase 7B inhibitor | 0.14 0.025 DBMET00676 | DBMET00676 | |
| 0.063 | 0.227 | 0.226 | Folate antagonist | 0.226 0.007 DBMET00676 | DBMET00676 | |
| 0.027 | 0.202 | 0.09 | Cyclin B3 inhibitor | 0.077 0.04 DBMET00772 0.09 0.033 DBMET00676 | DBMET00676 | |
| 0.114 | 0.291 | 0.218 | DNA synthesis inhibitor | 0.218 0.097 DBMET00772 0.213 0.103 DBMET00676 | DBMET00772 | |
| 0.097 | 0.282 | 0.207 | 5 Hydroxytryptamine 1E antagonist | 0.207 0.123 DBMET00676 | DBMET00676 | |
| 0.016 | 0.202 | 0.05 | Argininosuccinate synthase inhibitor | 0.05 0.047 DBMET00676 | DBMET00676 | |
| 0.061 | 0.248 | 0.112 | CDK3/cyclin E inhibitor | 0.112 0.067 DBMET00676 | DBMET00676 | |
| 0.061 | 0.249 | 0.24 | Protein kinase (CK1) gamma 1 inhibitor | 0.24 0.031 DBMET00676 | DBMET00676 | |
| 0.045 | 0.236 | 0.111 | Dual specificity tyrosine-phosphorylation-regulated kinase 4 inhibitor | 0.111 0.11 DBMET00676 | DBMET00676 | |
| 0.061 | 0.272 | 0.115 | Cell wall synthesis inhibitor | 0.115 0.107 DBMET00772 | DBMET00772 | |
| 0.014 | 0.229 | 0.057 | 5 Hydroxytryptamine 6 antagonist | 0.057 0.039 DBMET00676 | DBMET00676 | |
| 0.012 | 0.231 | 0.073 | Benzodiazepine receptor peripheral-type antagonist | 0.073 0.004 DBMET00772 | DBMET00772 | |
| 0.051 | 0.272 | 0.21 | Aryl hydrocarbon receptor agonist | 0.21 0.097 DBMET00676 | DBMET00676 | |
| 0.046 | 0.27 | 0.202 | Clk dual-specificity kinase inhibitor | 0.202 0.078 DBMET00676 | DBMET00676 | |
| 0.045 | 0.281 | 0.152 | Protein kinase C nu inhibitor | 0.152 0.069 DBMET00772 | DBMET00772 | |
| 0.066 | 0.305 | 0.138 | NOS3 expression enhancer | 0.138 0.086 DBMET00676 | DBMET00676 | |
| 0.051 | 0.294 | 0.176 | Dual specificity tyrosine-phosphorylation regulated kinase 1A inhibitor | 0.176 0.109 DBMET00676 | DBMET00676 | |
| 0.019 | 0.267 | 0.052 | Dopamine beta hydroxylase inhibitor | 0.052 0.026 DBMET00676 | DBMET00676 | |
| 0.051 | 0.3 | 0.193 | LIM domain kinase 1 inhibitor | 0.193 0.066 DBMET00676 | DBMET00676 | |
| 0.051 | 0.304 | 0.182 | Dyrk kinase inhibitor | 0.182 0.109 DBMET00676 | DBMET00676 | |
| 0.019 | 0.274 | 0.092 | Aurora-A kinase inhibitor | 0.092 0.073 DBMET00676 | DBMET00676 | |
| 0.052 | 0.315 | 0.195 | Anesthetic general | 0.195 0.077 DBMET00772 | DBMET00772 | |
| 0.037 | 0.301 | 0.253 | Protein kinase (CK1) gamma inhibitor | 0.253 0.029 DBMET00676 | DBMET00676 | |
| 0.03 | 0.299 | 0.095 | Protein kinase C mu inhibitor | 0.095 0.062 DBMET00772 | DBMET00772 | |
| 0.017 | 0.293 | 0.186 | Protein kinase (CK1) delta inhibitor | 0.186 0.034 DBMET00676 | DBMET00676 | |
| 0.019 | 0.309 | 0.09 | Protein kinase A inhibitor | 0.09 0.052 DBMET00676 | DBMET00676 | |
| 0.034 | 0.324 | 0.179 | Ribosomal protein S6 kinase inhibitor | 0.179 0.047 DBMET00676 | DBMET00676 | |
| 0.026 | 0.318 | 0.157 | Lck kinase inhibitor | 0.157 0.061 DBMET00676 | DBMET00676 | |
| 0.025 | 0.319 | 0.064 | Interferon inducer | 0.064 0.044 DBMET00676 | DBMET00676 | |
| 0.022 | 0.319 | 0.194 | Protein kinase (CK1) inhibitor | 0.194 0.042 DBMET00676 | DBMET00676 | |
| 0.008 | 0.306 | 0.107 | Raf kinase C inhibitor | 0.107 0.023 DBMET00676 | DBMET00676 | |
| 0.082 | 0.392 | 0.166 | MAP-kinase-activated kinase 5 inhibitor | 0.166 0.154 DBMET00772 | DBMET00772 | |
| 0.005 | 0.326 | 0.018 | O6-alkylguanine-DNA alkyltransferase inhibitor | 0.018 0.01 DBMET00676 | DBMET00676 | |
| 0.001 | 0.328 | 0.008 | Phosphoribosylglycinamide formyltransferase inhibitor | 0.008 0.005 DBMET00676 | DBMET00676 | |
| 0.021 | 0.354 | 0.075 | Interferon agonist | 0.075 0.06 DBMET00676 | DBMET00676 | |
| 0.005 | 0.339 | 0.017 | Integrin beta6 antagonist | 0.017 0.005 DBMET00676 | DBMET00676 | |
| 0.073 | 0.41 | 0.128 | MAP kinase kinase 4 inhibitor | 0.128 0.121 DBMET00676 | DBMET00676 | |
| 0.063 | 0.402 | 0.139 | Phospholipase C inhibitor | 0.139 0.131 DBMET00676 | DBMET00676 | |
| 0.036 | 0.384 | 0.134 | Protein kinase (CK1) gamma 3 inhibitor | 0.134 0.108 DBMET00676 | DBMET00676 | |
| 0.017 | 0.371 | 0.081 | Secretase beta inhibitor | 0.081 0.035 DBMET00676 | DBMET00676 | |
| 0.042 | 0.418 | 0.207 | Antimitotic | 0.207 0.08 DBMET00676 | DBMET00676 | |
| 0.019 | 0.442 | 0.136 | Protein kinase (CK1) gamma 2 inhibitor | 0.136 0.055 DBMET00676 | DBMET00676 | |
| 0.018 | 0.451 | 0.11 | Nitric-oxide synthase inhibitor | 0.11 0.046 DBMET00676 | DBMET00676 | |
| 0.027 | 0.473 | 0.212 | TRKC antagonist | 0.212 0.062 DBMET00676 | DBMET00676 | |
| 0.037 | 0.488 | 0.078 | T cell inhibitor | 0.078 0.074 DBMET00676 | DBMET00676 | |
| 0.004 | 0.465 | 0.033 | Prostacyclin antagonist | 0.033 0.023 DBMET00676 | DBMET00676 | |
| 0.008 | 0.48 | 0.174 | Check point kinase 2 inhibitor | 0.174 0.024 DBMET00676 | DBMET00676 | |
| 0.004 | 0.49 | 0.038 | 1,3-Beta-glucan synthase inhibitor | 0.038 0.005 DBMET00772 | DBMET00772 | |
| 0.018 | 0.534 | 0.146 | Proto-oncogene tyrosine-protein kinase Yes inhibitor | 0.146 0.063 DBMET00676 | DBMET00676 | |
| 0.004 | 0.604 | 0.021 | Factor IX inhibitor | 0.021 0.011 DBMET00676 | DBMET00676 | |
| 0.026 | 0.668 | 0.087 | Toll-Like receptor 3 antagonist | 0.087 0.076 DBMET00676 | DBMET00676 | |
| 0.012 | 0.768 | 0.112 | Factor IXa inhibitor | 0.112 0.007 DBMET00676 | DBMET00676 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |